ORPHA:31740
Hypersensitivity pneumonitis
Also known as: Extrinsic allergic alveolitis
Publications
11,058
Trials
19
Interventional, condition-specific
Researchers
1,244
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, immunologically mediated, interstitial lung disease characterized by respiratory symptoms (cough, dyspnea) due to sensitization and subsequent hypersensitivity to environmental antigens. The disorder may be accompanied by systemic manifestations (weight loss, fatigue).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017853
- MeSH:D000542
- UMLS:C0002390
- NCIT:C34369
Additional Mondo synonyms (6)
HP · allergic form of pneumonitis · allergic pneumonitis · exogen allergic alveolitis · extrinsic allergic alveolitis · hypersensitivity pneumonitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
11,058 matched papers (6,116 in last 10 years) Source
- Phenotype characterisedPresent
33 HPO annotations (e.g. Hypersensitivity pneumonitis; Increased circulating IgE concentration; Elevated erythrocyte sedimentation rate) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
19 matched on ClinicalTrials.gov (4 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
33
Associated phenotypes · MONDO:0017853
- Hypersensitivity pneumonitis
- Increased circulating IgE concentration
- Elevated erythrocyte sedimentation rate
- Elevated circulating C-reactive protein concentration
Showing 4 of 33 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0017853
- PIRFENIDONE·phase 2
- PREDNISOLONE·phase 2
- RITUXIMAB·phase 2
CTD chemicals (MyDisease.info)
7 associated chemicals · 10 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Air Pollutants · marker/mechanism
- Amiodarone · marker/mechanism
- Cocaine · marker/mechanism
- Ovalbumin · marker/mechanism
- Particulate Matter · marker/mechanism
- Pravastatin · marker/mechanism
- trofosfamide · marker/mechanism
Pathways: FoxO signaling pathway; Peroxisome; Longevity regulating pathway; Longevity regulating pathway - multiple species; Huntington's disease; Disease; Cellular responses to stress; Detoxification of Reactive Oxygen Species
Literature
Is anyone studying this?
11,058
11,058 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
11,058 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
6,116 in the last 10 years · low confidence
Phrase hits: 11,058 · MeSH hits: 0
Who's working on it?
1,244
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Adegunsoye A10 papers · 2026
Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, United States.
Papers in Europe PMC - 02Fernández Pérez ER9 papers · 2026
Division of Pulmonary, Critical Care and Sleep Medicine National Jewish Health Denver, Colorado.
Papers in Europe PMC - 03Lynch DA8 papers · 2026
Division of Radiology National Jewish Health Denver, Colorado.
Papers in Europe PMC - 04Ogura T8 papers · 2026
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama, 236-0051, Japan.
Papers in Europe PMC - 05Takemura T8 papers · 2026
Department of Pathology, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama, 236-0051, Japan.
Papers in Europe PMC - 06Johannson KA7 papers · 2026
Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada kerri.johannson@ahs.ca.
Papers in Europe PMC - 07Adams TN6 papers · 2026
Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Papers in Europe PMC - 08Chaudhary S6 papers · 2026
Respiratory Medicine, Guy's and St Thomas' NHS Foundation Trust, London, England, UK.
Papers in Europe PMC - 09Hagiwara E6 papers · 2026
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama, 236-0051, Japan.
Papers in Europe PMC - 10Moua T6 papers · 2026
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
19
interventional trials for this specific condition
19 interventional trials matched this specific condition name; 4 currently recruiting in our sample. 56 trials are registered for pneumonitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
19 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94.6th percentile).
low confidence · 94.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
19 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05365802·RECRUITING·FAPI PET for Lung Fibrosis
Not reviewed·Conditions: Interstitial Lung Disease · Idiopathic Interstitial Pneumonias · Drug-Induced Pneumonitis · Hypersensitivity Pneumonitis·Matched via name phrase
- NCT03800017·RECRUITING·Skeletal Muscle Function in Interstitial Lung Disease
Not reviewed·Conditions: Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis · Hypersensitivity Pneumonitis · Scleroderma·Matched via name phrase
- NCT07210008·NOT YET RECRUITING·"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis"
Not reviewed·Conditions: Hypersensitivity Pneumonitis·Matched via name phrase
- NCT06811389·RECRUITING·Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
Not reviewed·Conditions: Hypersensitivity Pneumonitis·Matched via name phrase
Broader category: pneumonitis
56
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07339644·RECRUITING·Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study
Not reviewed·Conditions: Lung Cancer (Including Metastatic Cancer) · Radiation Pneumonitis · Radiation-induced Lung Injury·Matched via name phrase
- NCT07186933·RECRUITING·Driving Pressure During Surgeries With High Risk for Postoperative Pulmonary Complications
Not reviewed·Conditions: Postoperative Pulmonary Atelectasis · Postoperative Pulmonary Complications · Postoperative Respiratory Failure · Postoperative Bronchospasm·Matched via name phrase
- NCT06688422·RECRUITING·Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Not reviewed·Conditions: Lung Cancer · Pneumonitis · Radiation-Induced Lung Injury · Immunotherapy-Induced Pneumonitis·Matched via name phrase
- NCT04676828·RECRUITING·Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer
Not reviewed·Conditions: Lung Cancer · Radiation-Induced Disorder · Radiation Pneumonitis · Pulmonary Disease·Matched via name phrase
- NCT06634056·RECRUITING·Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
Not reviewed·Conditions: Non-Small Cell Lung Cancer · Radiation Induced Lung Injury (RILI)·Matched via name phrase
- NCT07554885·NOT YET RECRUITING·Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation
Not reviewed·Conditions: Immune Checkpoint Inhibitor-Related Pneumonitis · Drug-Related Side Effects and Adverse Reactions · Neoplasms·Matched via name phrase
- NCT05189496·RECRUITING·Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis
Not reviewed·Conditions: Radiation Pneumonitis·Matched via name phrase
- NCT07599111·NOT YET RECRUITING·Exploratory Study on the Efficacy and Safety of Nebulized hUC-MSC-Derived Exosomes for Non-Acute CIP
Not reviewed·Conditions: Pneumonitis, Interstitial · Immune Checkpoint Inhibitors (ICIs) · Mesenchymal Stem Cells · Exosomes·Matched via name phrase
- NCT06860542·RECRUITING·Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
Not reviewed·Conditions: Pneumonitis · Immune-related Adverse Event·Matched via name phrase
- NCT05455034·RECRUITING·Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis
Not reviewed·Conditions: Pneumonitis·Matched via name phrase
- NCT03803787·RECRUITING·Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
Not reviewed·Conditions: Radiation Pneumonitis·Matched via name phrase
Observational and natural-history studies
15 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05392881·RECRUITING·Interstitial Lung Disease Research Unit Biobank
Not reviewed·Conditions: Interstitial Lung Disease · Sarcoidosis · Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis·Matched via name phrase
- NCT05727852·ENROLLING BY INVITATION·Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Not reviewed·Conditions: Chronic Respiratory Diseases · Cystic Fibrosis · Lymphangioleiomyomatosis · Hypersensitivity Pneumonitis·Matched via name phrase
- NCT06644144·RECRUITING·P4O2 ILD Extension
Not reviewed·Conditions: Interstitial Lung Disease · Pulmonary Fibrosis · Interstitial Lung Fibrosis · IPF·Matched via name phrase
- NCT05549635·RECRUITING·Database and Biobank of Patients With Hypersensitivity Pneumonitis
Not reviewed·Conditions: Hypersensitivity Pneumonitis·Matched via name phrase
- NCT04896138·ENROLLING BY INVITATION·University of Virginia Natural History Study
Not reviewed·Conditions: Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis · Sarcoidosis · Connective Tissue Diseases·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 50 · after dedupe 50 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 50 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (50)
- ctis·2025-522834-30-01·Authorised·Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15819396·Recruiting·A Phase I/IIa trial of KJ-103 in solid cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN24846895·Recruiting·A study to explore the effect of immunotherapy drug, tebentafusp, on patients with clear cell sarcoma (ultra-rare, aggressive type of soft tissue sarcoma that primarily affects young adults)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13351736·Recruiting·A study of amivantamab in addition to standard of care agents compared with standard of care in participants with recurrent/metastatic head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN67463316·Recruiting·Is datopotamab deruxtecan plus durvalumab more effective than datopotamab deruxtecan alone at treating patients with metastatic breast cancer?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12595783·Recruiting·NG-350A plus chemoradiotherapy for locally advanced rectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58111563·Recruiting·Testing oral corticosteroids versus placebo for the treatment of fibrotic hypersensitivity pneumonitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16463547·Recruiting·CRISTAL-APC - a trial of chemokine receptor inhibition for patients with pancreatic cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN39913423·Recruiting·A randomized, open-label phase 3 study of amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in participants with KRAS/NRAS and BRAF wildtype recurrent, unresectable or metastatic colorectal cancer who have received prior chemotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11118663·Recruiting·A randomized, open-label phase 3 study of amivantamab and mFOLFOX6 or FOLFIRI versus cetuximab and mFOLFOX6 or FOLFIRI as first-line treatment in participants with KRAS/NRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11908197·Recruiting·Disitamab vedotin with pembrolizumab vs chemotherapy in previously untreated urothelial cancer expressing HER2
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12532102·Recruiting·A trial looking at different treatments for neuroblastoma which has come back after initial therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15038320·Recruiting·A phase 1b/2 study of JNJ-90014496 in Adult Participants with B-Cell non-Hodgkin lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57038506·Recruiting·A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of the study drug MYTX-011 in Subjects with Non-Small Cell Lung Cancer Cell Lung Cancer – KisMET-01
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45104480·Recruiting·A modular, multi-part, multi-arm, open-label, phase I/II study to evaluate the safety and tolerability of GRWD5769 alone and in combination with anticancer treatments in patients with solid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98745687·No longer recruiting·A Phase Ib/II, open-label study of amivantamab monotherapy and amivantamab in addition to other therapeutic agents in participants with head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63154609·Recruiting·A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17666983·No longer recruiting·A Study of JNJ-90009530 in Relapsed or Refractory B-Cell non-Hodgkin Lymphoma (r/r B-NHL)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12434145·Recruiting·A first in human study to investigate the safety and tolerability of CV6-168 in combination with anti-cancer treatments in patients with advanced cancer.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16573769·No longer recruiting·DOMENICA: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus dostarlimab in a first-line advanced/metastatic setting
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12812346·Recruiting·Study of etoposide carboplatin chemotherapy in combination with pembrolizumab and lenvatinib therapy in advanced high-grade neuroendocrine tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15960722·No longer recruiting·Trastuzumab deruxtecan treatment for biomarker-selected (HER2 and ctDNA) patients with gastrooesophageal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50261938·Suspended·Study to evaluate treatment efficacy by monitoring minimal residual disease in an early breast cancer population
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10511385·No longer recruiting·A trial of 3-weekly cemiplimab in patients with locally advanced basal cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53212600·Stopped·Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hypersensitivity pneumonitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hypersensitivity pneumonitis" OR "Extrinsic allergic alveolitis" OR "allergic form of pneumonitis" OR "allergic form of the pneumonitis" OR "allergic pneumonitis" OR "exogen allergic alveolitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hypersensitivity pneumonitis" OR "Extrinsic allergic alveolitis" OR "allergic form of pneumonitis" OR "allergic form of the pneumonitis" OR "allergic pneumonitis" OR "exogen allergic alveolitis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 19 interventional · 15 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"pneumonitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HP
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (11058) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T23:29:22.358Z
